The global hepatitis C drug market accounted for USD 25.15 billion in 2023 and is expected to reach USD 111.86 billion by 2034 with a CAGR of 14.53% during the forecast period 2024-2034. The market will grow as a result of factors such as the increasing prevalence of hepatitis C, improved diagnostics and growing awareness, government initiatives, and screening programs, the development of new and advanced drugs, the emphasis on patient affordability and treatment accessibility, the rise in demand for fixed-dose combinations, and strategic alliances and collaborations.
Millions of individuals worldwide suffer from hepatitis C, which if untreated can have serious consequences for the liver. Hepatitis C medications have a sizable market demand due to the high disease burden and the requirement for efficient treatment choices. Numerous countries are starting specific initiatives for the diagnosis and treatment of hepatitis C. For instance, Gilead reported encouraging outcomes from a Phase 3 trial assessing their investigational treatment for long-term hepatitis C virus (HCV) infection in April 2022. In patients with chronic HCV genotype 1-6 infection who had not received treatment before, the trial showed the therapy's great efficacy and safety.
By product type, the fixed-dose combination segment accounted for the highest revenue-grossing segment in the global hepatitis C drug market in 2023 owing to the convenience of simplified dosing regimens, improved patient adherence, and enhanced treatment outcomes. For instance, Merck reported favorable outcomes from a Phase 3 trial assessing their investigational treatment for chronic hepatitis C virus (HCV) infection in February 2022. In patients with chronic HCV genotype 1-6 infection who had not received treatment before, the trial showed the therapy's great efficacy and safety. Additionally, the NS5A inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to their potent antiviral activity, favorable safety profiles, and effectiveness against a broad range of hepatitis C virus genotypes.
By disease type, the chronic hepatitis C segment accounted for the highest revenue-grossing segment in the global hepatitis C drug market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of chronic infections, rising awareness, and ongoing efforts to eliminate the disease. For instance, Bristol Myers Squibb announced positive top-line data in November 2022 from a Phase 3 trial assessing their investigational medication for long-term hepatitis C virus (HCV) infection. In individuals with chronic HCV genotype 1-6 infection, the trial showed significant rates of sustained virologic response 12 weeks after treatment.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global hepatitis C drug market in 2023 owing to the availability of specialized medical facilities, high patient volumes, and the administration of complex treatments often required for hepatitis C management. For instance, in September 2022, AbbVie revealed that a Phase 3 trial assessing its combination medication for chronic hepatitis C virus (HCV) infection had produced encouraging findings. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of telemedicine, the convenience of home delivery, and the expansion of digital healthcare platforms facilitating access to hepatitis C medications.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of advanced healthcare infrastructure, high awareness about hepatitis C, favorable reimbursement policies, and extensive research and development activities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the large patient population, increasing awareness, improving healthcare infrastructure, rising disposable incomes, and expanding access to hepatitis C screening and treatment programs. For instance, Roche reported encouraging findings from a Phase 2 trial assessing their investigational medication for hepatitis C virus (HCV) infection in July 2022. In individuals with chronic HCV genotype 1-3 infection, the trial demonstrated a high level of therapy efficacy and safety.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Millions of individuals worldwide suffer from hepatitis C, which if untreated can have serious consequences for the liver. Hepatitis C medications have a sizable market demand due to the high disease burden and the requirement for efficient treatment choices. Numerous countries are starting specific initiatives for the diagnosis and treatment of hepatitis C. For instance, Gilead reported encouraging outcomes from a Phase 3 trial assessing their investigational treatment for long-term hepatitis C virus (HCV) infection in April 2022. In patients with chronic HCV genotype 1-6 infection who had not received treatment before, the trial showed the therapy's great efficacy and safety.
By product type, the fixed-dose combination segment accounted for the highest revenue-grossing segment in the global hepatitis C drug market in 2023 owing to the convenience of simplified dosing regimens, improved patient adherence, and enhanced treatment outcomes. For instance, Merck reported favorable outcomes from a Phase 3 trial assessing their investigational treatment for chronic hepatitis C virus (HCV) infection in February 2022. In patients with chronic HCV genotype 1-6 infection who had not received treatment before, the trial showed the therapy's great efficacy and safety. Additionally, the NS5A inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to their potent antiviral activity, favorable safety profiles, and effectiveness against a broad range of hepatitis C virus genotypes.
By disease type, the chronic hepatitis C segment accounted for the highest revenue-grossing segment in the global hepatitis C drug market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of chronic infections, rising awareness, and ongoing efforts to eliminate the disease. For instance, Bristol Myers Squibb announced positive top-line data in November 2022 from a Phase 3 trial assessing their investigational medication for long-term hepatitis C virus (HCV) infection. In individuals with chronic HCV genotype 1-6 infection, the trial showed significant rates of sustained virologic response 12 weeks after treatment.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global hepatitis C drug market in 2023 owing to the availability of specialized medical facilities, high patient volumes, and the administration of complex treatments often required for hepatitis C management. For instance, in September 2022, AbbVie revealed that a Phase 3 trial assessing its combination medication for chronic hepatitis C virus (HCV) infection had produced encouraging findings. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of telemedicine, the convenience of home delivery, and the expansion of digital healthcare platforms facilitating access to hepatitis C medications.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of advanced healthcare infrastructure, high awareness about hepatitis C, favorable reimbursement policies, and extensive research and development activities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the large patient population, increasing awareness, improving healthcare infrastructure, rising disposable incomes, and expanding access to hepatitis C screening and treatment programs. For instance, Roche reported encouraging findings from a Phase 2 trial assessing their investigational medication for hepatitis C virus (HCV) infection in July 2022. In individuals with chronic HCV genotype 1-3 infection, the trial demonstrated a high level of therapy efficacy and safety.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product Type, Disease Type, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Hepatitis C Drug Market Report 2023 - 2034
Hepatitis C Drug Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- NSSA Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Others
Hepatitis C Drug Market Analysis & Forecast by Disease Type 2023 - 2034 (Revenue USD Bn)
- Acute Hepatitis C
- Chronic Hepatitis C
Hepatitis C Drug Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Hepatitis C Drug Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Hepatitis C Drug Market: Drug Type Estimates & Trend Analysis
8. Hepatitis C Drug Market: Disease Type Estimates & Trend Analysis
9. Hepatitis C Drug Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Hepatitis C Drug Market
12. Europe Global Hepatitis C Drug Market
13. Asia Pacific Global Hepatitis C Drug Market
14. Latin America Global Hepatitis C Drug Market
15. MEA Global Hepatitis C Drug Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Gilead Sciences Inc.
- AbbVie Inc.
- Merck & Co. Inc.
- Bristol Myers Squibb Company
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Novartis International AG
- AbbVie
- Vertex Pharmaceuticals Incorporated
- Eisai Co. Ltd.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- Pfizer Inc.
- Daiichi Sankyo Company
- Limited.
